News

The UK’s medical device industry is experiencing exceptional growth, with fresh figures from the Medicines and Healthcare products Regulatory Agency (MHRA) revealing a record number of clinical investigations approved in 2025. Authorisations increased by 17% compared with 2024, highlighting the UK’s rising status as a global proving ground for cutting-edge technologies—particularly in neurotechnology and artificial intelligence.

For innovators, the signal is unmistakable: the UK is establishing itself as one of the most responsive and innovation-friendly regulatory landscapes for medical devices worldwide.

Neurotechnology Takes Centre Stage

The sharpest expansion has been in neurotechnology. Clinical investigations in this field have doubled since 2024 and now account for around a quarter of all UK submissions. This momentum mirrors a global drive to tackle complex neurological disorders such as dementia, Parkinson’s disease and epilepsy—conditions where conventional therapies often provide limited benefit.

Among the MHRA’s recent approvals are a feasibility study exploring deep brain stimulation for addiction, and a pioneering first-in-human paediatric trial led by Great Ormond Street Hospital, UCL and the University of Oxford. The latter will evaluate a rechargeable brain-stimulation implant designed to lower seizure frequency in children with severe, treatment-resistant epilepsy.

Momentum Builds for AI-Enabled Devices

Artificial intelligence is also gaining traction. Newly approved studies are investigating technologies that enable earlier disease detection, enhance clinical decision-making and tailor treatments to individual patients. Recent clearances include a digital therapeutic for chronic obstructive pulmonary disease that adjusts treatment guidance in real time. Ophthalmology is another growing focus, with companies trialling novel methods to protect and restore vision.

Collectively, these developments signal a future defined by quicker diagnoses, more targeted therapies and faster patient access to breakthrough innovations.

Supporting the Next Generation of Innovators

To maintain this trajectory, the MHRA has introduced initiatives aimed at easing the path for smaller enterprises. From January 2026, micro and small UK-based businesses will be eligible for a fee-waiver pilot intended to remove financial hurdles that can impede early-stage development.

In parallel, the agency is contributing to a nationwide collaboration led by Newcastle University to refresh national guidance on neurotechnology research—an update expected to simplify study setup for devices that interface with the brain and nervous system.